About
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (HIF) biology. AkebiaÍs lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. AkebiaÍs global Phase 3 program for vadadustat, which includes the PRO2TECT studies for non-dialysis patients with anemia associated with chronic kidney disease and the INNO2VATE studies for dialysis-dependent patients, is currently ongoing. For more information, please visit our website at www.akebia.com.
- Company Name:Akebia Therapeutics
(View Trends)
-
Headquarters: (View Map)Cambridge, MA, United States
-
Biotechnology
-
200 - 500 employees
Site Traffic
- 2240466 Global Rank
- 576727 United States
Traffic Sources
-
Search58.59%
-
Direct36.01%
-
Referrals5.40%
-
Display0.00%
-
Mail0.00%
-
Social0.00%
Powered by
![]()
Alexa Traffic Data
Global Rank
598,663
218,029
Links In Count
28
5
United States Rank
142,435
261,307
United States Page Views
97.3%
11.6%
Akebia Therapeutics receives up to 0.03M pageviews per day, in countries such as United States.
They are headquartered at Cambridge, MA, United States, and have 2 advertising & marketing contacts listed on Kochava. Akebia Therapeutics works with Advertising technology companies such as DoubleClick.Net, Consent Management Platform API v 2.0.
They are headquartered at Cambridge, MA, United States, and have 2 advertising & marketing contacts listed on Kochava. Akebia Therapeutics works with Advertising technology companies such as DoubleClick.Net, Consent Management Platform API v 2.0.
